FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.10  |  FHIR Version n/a  User: [n/a]

22054211000001109: Kerstipon 1.5mg capsules (Aspire Pharma Ltd) (product)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 03-Apr 2013. Module: SNOMED CT United Kingdom drug extension module

Descriptions:

Id Description Lang Type Status Case? Module
73087601000001110 Kerstipon 1.5mg capsules (Aspire Pharma Ltd) (product) en Fully specified name Active Entire term case sensitive SNOMED CT United Kingdom drug extension module
73087701000001117 Kerstipon 1.5mg capsules (Aspire Pharma Ltd) en Synonym Active Entire term case sensitive SNOMED CT United Kingdom drug extension module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Kerstipon 1.5mg capsules (Aspire Pharma Ltd) Has NHS dm+d (dictionary of medicines and devices) controlled drug category Controlled drug category No Controlled Drug Status true Inferred relationship Existential restriction modifier
Kerstipon 1.5mg capsules (Aspire Pharma Ltd) Has NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction indicator NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction not available true Inferred relationship Existential restriction modifier
Kerstipon 1.5mg capsules (Aspire Pharma Ltd) Is a Product containing precisely rivastigmine (as rivastigmine tartrate) 1.5 milligram/1 each conventional release oral capsule true Inferred relationship Existential restriction modifier
Kerstipon 1.5mg capsules (Aspire Pharma Ltd) Has active ingredient Rivastigmine tartrate false Inferred relationship Existential restriction modifier
Kerstipon 1.5mg capsules (Aspire Pharma Ltd) Has manufactured dose form Conventional release oral capsule true Inferred relationship Existential restriction modifier
Kerstipon 1.5mg capsules (Aspire Pharma Ltd) VMP prescribing status (attribute) VMP valid as a prescribable product true Inferred relationship Existential restriction modifier
Kerstipon 1.5mg capsules (Aspire Pharma Ltd) VMP non-availability indicator Available true Inferred relationship Existential restriction modifier
Kerstipon 1.5mg capsules (Aspire Pharma Ltd) Has specific active ingredient Rivastigmine tartrate true Inferred relationship Existential restriction modifier
Kerstipon 1.5mg capsules (Aspire Pharma Ltd) Has dispensed dose form Capsule true Inferred relationship Existential restriction modifier
Kerstipon 1.5mg capsules (Aspire Pharma Ltd) Has NHS dm+d (dictionary of medicines and devices) basis of strength substance Rivastigmine true Inferred relationship Existential restriction modifier
Kerstipon 1.5mg capsules (Aspire Pharma Ltd) Has excipient Excipient not declared true Inferred relationship Existential restriction modifier
Kerstipon 1.5mg capsules (Aspire Pharma Ltd) Is a Actual medicinal product true Inferred relationship Existential restriction modifier
Kerstipon 1.5mg capsules (Aspire Pharma Ltd) Is a Kerstipon true Inferred relationship Existential restriction modifier
Kerstipon 1.5mg capsules (Aspire Pharma Ltd) Has basis of strength substance Rivastigmine true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group
Kerstipon 1.5mg capsules (Aspire Pharma Ltd) 28 capsule 4 x 7 capsules Has AMP True Kerstipon 1.5mg capsules (Aspire Pharma Ltd) Inferred relationship Existential restriction modifier

This concept is not in any reference sets

Back to Start